NCT03535545View on ClinicalTrials.gov

Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients

PHASE1RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Pulmonary FibrosisLung Cancer

Interventions

DRUG

[68Ga]CBP8

Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.

DIAGNOSTIC_TEST

PET Imaging

All subjects will undergo PET imaging after administration of \[68Ga\]CBP8.

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Massachusetts General Hospital

OTHER

NCT03535545 - Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients | Biotech Hunter | Biotech Hunter